HFA 24: Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF

Published: 13 May 2024

  • Views:

    Views Icon 108
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.

PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure patients. The Cordella device is a novel system for monitoring ambulatory pulmonary artery pressure. The device comes packaged with a broader range of home disease management monitoring systems, including access to vital signs including weight, blood pressure and heart rate.

Key findings showed that the Cordella system was safe in regard to freedom from device implant complications and sensor failure (<1%). The device was also found to be effective in regard to event rates.

Interview Questions:

  1. What are the unmet needs of NYHA Class III Patients?
  2. Could you tell us more about the Cordella sensor system?
  3. What is the patient population and study design?
  4. What are your key findings?
  5. What are your take-home messages?
  6. What further study is needed?

Recorded on-site at HFA 2024, Lisbon.
Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Jordan Rance

Videographer: Tom Green, Oliver Miles


You must be to comment. If you are not registered, you can register here.
Mohammed Elmobarak
Great,Thank you sir.
Mohammed Elmobarak